| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.70 |
| 52 Week High | CN¥16.40 |
| 52 Week Low | CN¥10.75 |
| Beta | 0.36 |
| 1 Month Change | 17.60% |
| 3 Month Change | 12.02% |
| 1 Year Change | -6.36% |
| 3 Year Change | -47.56% |
| 5 Year Change | 33.54% |
| Change since IPO | 390.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603707 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 3.9% | 5.6% | 3.1% |
| 1Y | -6.4% | -11.0% | -13.1% |
Return vs Industry: 603707 exceeded the CN Pharmaceuticals industry which returned -11% over the past year.
Return vs Market: 603707 exceeded the CN Market which returned -13.1% over the past year.
Price Volatility
| 603707 volatility | |
|---|---|
| 603707 Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 603707 has not had significant price volatility in the past 3 months.
Volatility Over Time: 603707's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,451 | Tang Yongqun | www.nkf-pharma.com |
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. The company provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium, cisatracurium, fulvestrant, doxercalciferol, milrinone lactate, fondaparinux sodium, phenylephrine, gemcitabine, levoleucovorin, carboplatin, cytarabine, bleomycin, topotecan hydrochloride, bendamustine HCL, bortezomib, clofarabine, busulfan, dactinomycin, azacitidine, mycophenolate mofetil, tigecycline, glycopyrrolate, melphalan, daptomycin, decitabine, haloperidol decanoate, carmustine, bivalirudin, dexmedetomidine, and neostigmine methylsulfate injections.
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Fundamentals Summary
| 603707 fundamental statistics | |
|---|---|
| Market cap | CN¥22.07b |
| Earnings (TTM) | -CN¥344.58m |
| Revenue (TTM) | CN¥3.63b |
6.1x
P/S Ratio-64.1x
P/E RatioIs 603707 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603707 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.63b |
| Cost of Revenue | CN¥3.24b |
| Gross Profit | CN¥383.22m |
| Other Expenses | CN¥727.80m |
| Earnings | -CN¥344.58m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 10.56% |
| Net Profit Margin | -9.50% |
| Debt/Equity Ratio | 45.3% |
How did 603707 perform over the long term?
See historical performance and comparison